Caphosol is also indicated for hyposalivation and xerostomia irrespective of the cause.
Bryan Morton, president and CEO of Eusa Pharma, said: “Caphosol’s introduction into the key French, German, Italian, Spanish, Benelux and UK markets, as well as a number of other EU countries, represents an important opportunity for Eusa to continue its rapid growth as the company commercializes its growing portfolio of specialty medicines on both sides of the Atlantic.
“Based on Eusa’s expanding market presence across the company’s areas of medical and geographic focus, we can increasingly compete with major players as a partner of choice for those seeking transatlantic commercial and late-stage development expertise.”